Ceftobiprole: a novel cephalosporin with activity against Gram-positive and Gram-negative pathogens, including methicillin-resistant Staphylococcus aureus (MRSA)

International Journal of Antimicrobial Agents

Volumn 34, Issue 1, 2009, Pages 1-7

  Barbour, April ^a   Schmidt, Stephan ^a   Rand, Kenneth H ^b   Derendorf, Hartmut ^a  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Ceftobiprole; MRSA; Pharmacodynamics; Pharmacokinetics

Indexed keywords

CEFTAZIDIME; CEFTOBIPROLE; CEFTOBIPROLE MEDOCARIL; CEPHALOSPORIN DERIVATIVE; UNCLASSIFIED DRUG; VANCOMYCIN; ZEFTERA;

ABDOMINAL PAIN; ANTIBACTERIAL ACTIVITY; AREA UNDER THE CURVE; CONSTIPATION; DIARRHEA; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG PROTEIN BINDING; DYSGEUSIA; FATIGUE; GLOMERULUS FILTRATION; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; GRAM POSITIVE BACTERIUM; GRAM POSITIVE INFECTION; HEADACHE; HUMAN; INJECTION SITE REACTION; MAXIMUM PLASMA CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; NONHUMAN; PENICILLIN RESISTANCE; PHARYNGITIS; PRIORITY JOURNAL; PRURITUS; RASH; SHORT SURVEY; SKIN INFECTION; SOMNOLENCE; STREPTOCOCCUS PNEUMONIAE; URINARY DYSFUNCTION; VOMITING;

ANTI-BACTERIAL AGENTS; CANADA; CEPHALOSPORINS; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; TREATMENT OUTCOME; UNITED STATES;

EID: 67349095601     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2008.12.012     Document Type: Short Survey

References (45)

1. U.S. Congress, Office of Technology Assessment. Impacts of antibiotic-resistant bacteria. Washington, DC: US Government Printing Office; September 1995. Report No. OTA-H-629.
2. Ibrahim E.H., Sherman G., Ward S., Fraser V.J., and Kollef M.H. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 118 (2000) 146-155
3. Jones R.N. Global epidemiology of antimicrobial resistance among community-acquired and nosocomial pathogens: a five-year summary from the SENTRY Antimicrobial Surveillance Program (1997-2001). Semin Respir Crit Care Med 24 (2003) 121-134
4. Gales A.C., Sader H.H., and Jones R.N. Respiratory tract pathogens isolated from patients hospitalized with suspected pneumonia in Latin America: frequency of occurrence and antimicrobial susceptibility profile: results from the SENTRY Antimicrobial Surveillance Program (1997-2000). Diagn Microbiol Infect Dis 44 (2002) 301-311
5. Mathai D., Lewis M.T., Kugler K.C., Pfaller M.A., and Jones R.N. Antibacterial activity of 41 antimicrobials tested against over 2773 bacterial isolates from hospitalized patients with pneumonia: I-results from the SENTRY Antimicrobial Surveillance Program (North America, 1998). Diagn Microbiol Infect Dis 39 (2001) 105-116
6. Fritsche T.R., Sader H.S., and Jones R.N. Potency and spectrum of garenoxacin tested against an international collection of skin and soft tissue infection pathogens: report from the SENTRY antimicrobial surveillance program (1999-2004). Diagn Microbiol Infect Dis 58 (2007) 19-26
7. Sievert D.M., Rudrik J.T., Patel J.B., McDonald L.C., Wilkins M.J., and Hageman J.C. Vancomycin-resistant Staphylococcus aureus in the United States, 2002-2006. Clin Infect Dis 46 (2008) 668-674
8. Gales A.C., Sader H.S., Andrade S.S., Lutz L., Machado A., and Barth A.L. Emergence of linezolid-resistant Staphylococcus aureus during treatment of pulmonary infection in a patient with cystic fibrosis. Int J Antimicrob Agents 27 (2006) 300-302
9. Rouse M.S., Steckelberg J.M., and Patel R. In vitro activity of ceftobiprole, daptomycin, linezolid, and vancomycin against methicillin-resistant staphylococci associated with endocarditis and bone and joint infection. Diagn Microbiol Infect Dis 58 (2007) 363-365
10. Jones R.N., Deshpande L.M., Mutnick A.H., and Biedenbach D.J. In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci. J Antimicrob Chemother 50 (2002) 915-932
11. Fritsche T.R., Sader H.S., and Jones R.N. Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005-2006). Diagn Microbiol Infect Dis 61 (2008) 86-95
12. Hebeisen P., Heinze-Krauss I., Angehrn P., Hohl P., Page M.G., and Then R.L. In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci. Antimicrob Agents Chemother 45 (2001) 825-836
13. Janssen-Ortho Inc. Zeftera product monograph. Toronto, Canada: Janssen-Ortho Inc.; 2008.
14. Barbour A, Murthy B, Schmidt S, Sabarinath S, Skee D, Tian H, et al. Soft-tissue penetration of ceftobiprole following single-dose administration in healthy adults. In: 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 25-28 October 2008; Washington, DC. Washington, DC: ASM Press; 2008.
15. Murthy B, Skee D, Wexler D, Balis D, Chang I, Desai-Kreiger D, et al. Pharmacokinetics of ceftobiprole following single and multiple intravenous infusions administered to healthy subjects. In: 17th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID); 31 March-4 April 2007; Munich, Germany. Basel, Switzerland: European Society of Clinical Microbiology and Infectious Diseases; 2007 [Abstract number: 1733_277].
16. Schmitt-Hoffmann A., Roos B., Schleimer M., Sauer J., Man A., Nashed N., et al. Single-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers. Antimicrob Agents Chemother 48 (2004) 2570-2575
17. Schmitt-Hoffmann A., Nyman L., Roos B., Schleimer M., Sauer J., Nashed N., et al. Multiple-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers. Antimicrob Agents Chemother 48 (2004) 2576-2580
18. Murthy B., and Schmitt-Hoffmann A. Pharmacokinetics and pharmacodynamics of ceftobiprole, an anti-MRSA cephalosporin with broad-spectrum activity. Clin Pharmacokinet 47 (2008) 21-33
19. Noel G.J., Bush K., Bagchi P., Ianus J., and Strauss R.S. A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections. Clin Infect Dis 46 (2008) 647-655
20. Nix D.E., Matthias K.R., and Ferguson E.C. Effect of ertapenem protein binding on killing of bacteria. Antimicrob Agents Chemother 48 (2004) 3419-3424
21. Zeitlinger M., Sauermann R., Fille M., Hausdorfer J., Leitner I., and Muller M. Plasma protein binding of fluoroquinolones affects antimicrobial activity. J Antimicrob Chemother 61 (2008) 561-567
22. Burkhardt O., Brunner M., Schmidt S., Grant M., Tang Y., and Derendorf H. Penetration of ertapenem into skeletal muscle and subcutaneous adipose tissue in healthy volunteers measured by in vivo microdialysis. J Antimicrob Chemother 58 (2006) 632-636
23. Muller M., Stass H., Brunner M., Moller J.G., Lackner E., and Eichler H.G. Penetration of moxifloxacin into peripheral compartments in humans. Antimicrob Agents Chemother 43 (1999) 2345-2349
24. Traunmuller F., Zeitlinger M., Zeleny P., Muller M., and Joukhadar C. Pharmacokinetics of single- and multiple-dose oral clarithromycin in soft tissues determined by microdialysis. Antimicrob Agents Chemother 51 (2007) 3185-3189
25. Stahl M., Bouw R., Jackson A., and Pay V. Human microdialysis. Curr Pharm Biotechnol 3 (2002) 165-178
26. Stahle L., Arner P., and Ungerstedt U. Drug distribution studies with microdialysis. III: extracellular concentration of caffeine in adipose tissue in man. Life Sci 49 (1991) 1853-1858
27. Schmitt-Hoffmann AH, Harsch M, Heep M, Schleimer M, Brown T, Man A, et al. BAL5788 in patients with complicated skin and skin structure infections cause by Gram-positive pathogens including methicillin-resistant Staphylococcus species. Interim pharmacokinetic results from 20 patients. In: 14th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID); 1-4 May 2004; Prague, Czech Republic. Basel, Switzerland: European Society of Clinical Microbiology and Infectious Diseases; 2004.
28. Noel G.J., Strauss R.S., Amsler K., Heep M., Pypstra R., and Solomkin J.S. Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria. Antimicrob Agents Chemother 52 (2008) 37-44
29. Schmitt-Hoffmann A. Influence of gender on the pharmacokinetics of BAL9141 after intravenous infusion of pro-drug BAL5788. In: 14th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID); 1-4 May 2004; Prague, Czech Republic. Basel, Switzerland: European Society of Clinical Microbiology and Infectious Diseases; 2004.
30. Deshpande L., Rhomberg P.R., Fritsche T.R., Sader H.S., and Jones R.N. Bactericidal activity of BAL9141, a novel parenteral cephalosporin against contemporary Gram-positive and Gram-negative isolates. Diagn Microbiol Infect Dis 50 (2004) 73-75
31. Davies T.A., Shang W., and Bush K. Activities of ceftobiprole and other β-lactams against Streptococcus pneumoniae clinical isolates from the United States with defined substitutions in penicillin-binding proteins PBP 1a, PBP 2b, and PBP 2×. Antimicrob Agents Chemother 50 (2006) 2530-2532
32. Davies T.A., Page M.G., Shang W., Andrew T., Kania M., and Bush K. Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae. Antimicrob Agents Chemother 51 (2007) 2621-2624
33. Queenan A.M., Shang W., Kania M., Page M.G., and Bush K. Interactions of ceftobiprole with β-lactamases from molecular classes A to D. Antimicrob Agents Chemother 51 (2007) 3089-3095
34. Bogdanovich T., Clark C., Ednie L., Lin G., Smith K., Shapiro S., et al. Activities of ceftobiprole, a novel broad-spectrum cephalosporin, against Haemophilus influenzae and Moraxella catarrhalis. Antimicrob Agents Chemother 50 (2006) 2050-2057
35. Deshpande L.M., and Jones R.N. Bactericidal activity and synergy studies of BAL9141, a novel pyrrolidinone-3-ylidenemethyl cephem, tested against streptococci, enterococci and methicillin-resistant staphylococci. Clin Microbiol Infect 9 (2003) 1120-1124
36. Bogdanovich T., Ednie L.M., Shapiro S., and Appelbaum P.C. Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin. Antimicrob Agents Chemother 49 (2005) 4210-4219
37. Azoulay-Dupuis E., Bedos J.P., Mohler J., Schmitt-Hoffmann A., Schleimer M., and Shapiro S. Efficacy of BAL5788, a prodrug of cephalosporin BAL9141, in a mouse model of acute pneumococcal pneumonia. Antimicrob Agents Chemother 48 (2004) 1105-1111
38. Chambers H.F. Evaluation of ceftobiprole in a rabbit model of aortic valve endocarditis due to methicillin-resistant and vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 49 (2005) 884-888
39. Arias C.A., Singh K.V., Panesso D., and Murray B.E. Evaluation of ceftobiprole medocaril against Enterococcus faecalis in a mouse peritonitis model. J Antimicrob Chemother 60 (2007) 594-598
40. Hersh A.L., Chambers H.F., Maselli J.H., and Gonzales R. National trends in ambulatory visits and antibiotic prescribing for skin and soft-tissue infections. Arch Intern Med 168 (2008) 1585-1591
41. Craig W.A. Does the dose matter?. Clin Infect Dis 33 Suppl. 3 (2001) S233-S237
42. Andes D, Craig W. In-vivo pharmacodynamics of RO 63-9141 against multiple bacterial pathogens. In: 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 17-20 September 2000; Toronto, Canada. Washington, DC: ASM Press; 2000.
43. Burgess D.S., and Frei C.R. Comparison of β-lactam regimens for the treatment of gram-negative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacodynamics. J Antimicrob Chemother 56 (2005) 893-898
44. Mouton J.W., Schmitt-Hoffmann A., Shapiro S., Nashed N., and Punt N.C. Use of Monte Carlo simulations to select therapeutic doses and provisional breakpoints of BAL9141. Antimicrob Agents Chemother 48 (2004) 1713-1718
45. Lodise Jr. T.P., Pypstra R., Kahn J.B., Murthy B.P., Kimko H.C., Bush K., et al. Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjects. Antimicrob Agents Chemother 51 (2007) 2378-2387